S&P 500   3,852.36
DOW   32,920.46
QQQ   300.92
15 Ways to Improve Your Credit
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
These 2 Healthcare Stocks Have Doubled in 2023
Pfizer Stock: What the Bulls and Bears are Getting Wrong
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
AMD Results Are No Reason To Buy Semiconductors... Yet
Bed Bath & Beyond Is Circling the Drain
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Allegro Microsystems Is A Well-Positioned Semiconductor Stock
Institutions are Buying up Procter & Gamble Shares, Should you?
S&P 500   3,852.36
DOW   32,920.46
QQQ   300.92
15 Ways to Improve Your Credit
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
These 2 Healthcare Stocks Have Doubled in 2023
Pfizer Stock: What the Bulls and Bears are Getting Wrong
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
AMD Results Are No Reason To Buy Semiconductors... Yet
Bed Bath & Beyond Is Circling the Drain
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Allegro Microsystems Is A Well-Positioned Semiconductor Stock
Institutions are Buying up Procter & Gamble Shares, Should you?
S&P 500   3,852.36
DOW   32,920.46
QQQ   300.92
15 Ways to Improve Your Credit
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
These 2 Healthcare Stocks Have Doubled in 2023
Pfizer Stock: What the Bulls and Bears are Getting Wrong
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
AMD Results Are No Reason To Buy Semiconductors... Yet
Bed Bath & Beyond Is Circling the Drain
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Allegro Microsystems Is A Well-Positioned Semiconductor Stock
Institutions are Buying up Procter & Gamble Shares, Should you?
S&P 500   3,852.36
DOW   32,920.46
QQQ   300.92
15 Ways to Improve Your Credit
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
These 2 Healthcare Stocks Have Doubled in 2023
Pfizer Stock: What the Bulls and Bears are Getting Wrong
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
AMD Results Are No Reason To Buy Semiconductors... Yet
Bed Bath & Beyond Is Circling the Drain
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Allegro Microsystems Is A Well-Positioned Semiconductor Stock
Institutions are Buying up Procter & Gamble Shares, Should you?
NASDAQ:IMMX

Immix Biopharma - IMMX Stock Forecast, Price & News

$2.63
+0.03 (+1.15%)
(As of 02/1/2023 12:00 AM ET)
Add
Compare
Today's Range
$2.42
▼
$2.71
50-Day Range
$1.05
▼
$2.63
52-Week Range
$0.68
▼
$5.37
Volume
134,726 shs
Average Volume
256,716 shs
Market Capitalization
$36.64 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Immix Biopharma MarketRank™ Forecast

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
2.93% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.96mentions of Immix Biopharma in the last 14 days
Based on 2 Articles This Week
Insider Trading
Acquiring Shares
$5,200 Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($0.43) to ($0.63) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.85 out of 5 stars

Medical Sector

804th out of 1,053 stocks

Pharmaceutical Preparations Industry

402nd out of 519 stocks

See Top Rated MarketRank™ Stocks Here

IMMX stock logo

About Immix Biopharma (NASDAQ:IMMX) Stock

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing various tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.

Receive IMMX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Immix Biopharma and its competitors with MarketBeat's FREE daily newsletter.

IMMX Stock News Headlines

January 26, 2023 | seekingalpha.com
IMMX Immix Biopharma, Inc.
January 13, 2023 | finance.yahoo.com
Immix Biopharma Doses Additional Patients in Ongoing Phase 1b/2a IMX-110 Monotherapy Clinical Trial
February 2, 2023 | Investor Place Media (Ad)
Cash Holders STILL Aren't Taking Steps to Prepare
Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.
January 6, 2023 | finance.yahoo.com
Immix Biopharma Subsidiary Nexcella, Inc. Announces Additional Positive NXC-201 Clinical Data Demonstrating 100% Complete Responses in Relapsed/Refractory AL Amyloidosis Patients, Duration of Response Not Yet Reached
December 28, 2022 | finance.yahoo.com
Nexcella, Inc., a subsidiary of Immix Biopharma, announces poster presentation at the European Society for Blood and Marrow Transplantation and European Hematology Association 5th Annual European CAR T-cell Meeting
December 20, 2022 | finance.yahoo.com
Immix Biopharma Announces 16th Patient Dosing in Ongoing Phase 1b/2a IMX-110 Monotherapy Clinical Trial
December 19, 2022 | finance.yahoo.com
ImmixBio Ships Tislelizumab for Patient Dosing in its Combination Clinical Trial with IMX-110 in Advanced Solid Tumors
December 15, 2022 | marketwatch.com
Immix Biopharma Shares Surge 61% On Positive Rates for Multiple Myeloma, AL Amyloidosis Drug
February 2, 2023 | Investor Place Media (Ad)
Cash Holders STILL Aren't Taking Steps to Prepare
Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.
December 14, 2022 | finance.yahoo.com
Immix Biopharma in-licenses NXC-201, BCMA-targeted Next-Generation CAR-T Therapy Demonstrating High Complete Response Rate in Heavily Pre-Treated Multiple Myeloma (71% Complete Responses) and AL Amyloidosis (100% Complete Responses)
December 13, 2022 | finance.yahoo.com
We're Hopeful That Immix Biopharma (NASDAQ:IMMX) Will Use Its Cash Wisely
December 12, 2022 | finance.yahoo.com
ImmixBio Releases and Ships Scaled-Up GMP Batches of IMX-110 for Clinical Trial Patient Dosing
November 11, 2022 | finance.yahoo.com
Immix Biopharma Receives Institutional Review Board Approval to Enroll Pediatric Patients in Upcoming IMX-110 Clinical Trial, Key Requirement for U.S. Food and Drug Administration Approval of Rare Pediatric Disease Priority Review Voucher
October 25, 2022 | finance.yahoo.com
Immix Biopharma to Present Milestones Achieved to Enable Kick-Off of 2 IMX-110 Clinical Trials at the 2022 ThinkEquity Conference on October 26
October 18, 2022 | finance.yahoo.com
ImmixBio Approves 4 Additional Clinical Trial Sites for IMX-110 Clinical Trials, Complementing Existing Soft Tissue Sarcoma Lead Site
September 20, 2022 | uk.finance.yahoo.com
Immix Biopharma (IMMX): Initiation — Fresh faces with a unique tissue-targeting therapy
September 19, 2022 | markets.businessinsider.com
Immix Biopharma (IMMX): Initiation Fresh faces with a unique tissue-targeting therapy
September 14, 2022 | nasdaq.com
Immix Biopharma, Inc.'s (NASDAQ:IMMX) recent US$2.9m market cap decline means a loss of US$194k for insiders who bought this year
September 7, 2022 | finance.yahoo.com
ImmixBio Completes GMP Manufacturing of Scaled-Up Batch of IMX-110 for Clinical Trials
August 23, 2022 | finance.yahoo.com
Insiders who bought in the last 12 months lose an additional US$175k as Immix Biopharma, Inc. (NASDAQ:IMMX) drops to US$28m
June 4, 2022 | seekingalpha.com
Immix, Bright Green top healthcare gainers; while Zosano, Immunic lead losers' pack
June 3, 2022 | seekingalpha.com
IMMX, ZY and SCOR among premarket gainers
May 21, 2022 | marketwatch.com
Immix Soars on Study Results
May 21, 2022 | nz.finance.yahoo.com
We Think Immix Biopharma (NASDAQ:IMMX) Can Afford To Drive Business Growth
May 20, 2022 | marketwatch.com
Immix Biopharma Shares 49% Higher After Data in Connective Tissue Cancer Mice Study
May 20, 2022 | seekingalpha.com
ImmixBio surges on mice data for lead candidate in connective tissue cancer
May 20, 2022 | nasdaq.com
ImmixBio: IMX-110 Shows Improved Survival In Connective Tissue Cancer Soft Tissue Sarcoma Mice Study
See More Headlines
Receive IMMX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Immix Biopharma and its competitors with MarketBeat's FREE daily newsletter.

IMMX Company Calendar

Last Earnings
11/09/2022
Today
2/01/2023
Next Earnings (Estimated)
2/08/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:IMMX
CUSIP
N/A
CIK
1873835
Web
www.immixbio.com
Phone
310-651-8041
Fax
N/A
Employees
2
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-24,380,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-149.98%
Return on Assets
-145.58%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
26.92
Quick Ratio
26.92

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.36 per share
Price / Book
1.93

Miscellaneous

Outstanding Shares
13,930,000
Free Float
6,782,000
Market Cap
$36.64 million
Optionable
Not Optionable
Beta
N/A

Key Executives

  • Dr. Ilya Rachman M.B.A. (Age 50)
    M.D., MBA, Ph.D., Co-Founder, Chairman & CEO
    Comp: $193.31k
  • Mr. Gabriel Morris B.A. (Age 36)
    CFO & Director
    Comp: $100k
  • Mr. Sean Senn J.D.
    M.B.A., M.Sc., MBA, MSc, Co-Founder
  • Dr. Vladimir P. Torchilin D.Sc. (Age 76)
    MSE, Ph.D., Scientific Co-Founder
  • Mr. Ben H. Lyon J.D.
    Exec. VP & Gen. Counsel
  • Dr. Graham Ross FFPM (Age 63)
    M.D., Acting Chief Medical Officer & Head of Clinical Devel.
  • Mr. Nandan Oza B.S. (Age 61)
    Head of Chemistry, Manufacturing & Control

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













IMMX Stock - Frequently Asked Questions

Should I buy or sell Immix Biopharma stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Immix Biopharma in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" IMMX shares.
View IMMX analyst ratings or view top-rated stocks.

How have IMMX shares performed in 2023?

Immix Biopharma's stock was trading at $2.29 at the beginning of the year. Since then, IMMX shares have increased by 14.8% and is now trading at $2.63.
View the best growth stocks for 2023 here.

Are investors shorting Immix Biopharma?

Immix Biopharma saw a decrease in short interest during the month of January. As of January 15th, there was short interest totaling 172,900 shares, a decrease of 19.2% from the December 31st total of 214,100 shares. Based on an average daily volume of 1,140,000 shares, the short-interest ratio is currently 0.2 days. Approximately 2.9% of the shares of the stock are short sold.
View Immix Biopharma's Short Interest.

When is Immix Biopharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 8th 2023.
View our IMMX earnings forecast.

How were Immix Biopharma's earnings last quarter?

Immix Biopharma, Inc. (NASDAQ:IMMX) announced its earnings results on Wednesday, November, 9th. The company reported ($0.11) EPS for the quarter.

When did Immix Biopharma IPO?

(IMMX) raised $23 million in an initial public offering (IPO) on Thursday, December 16th 2021. The company issued 4,200,000 shares at $5.00-$6.00 per share.

What is Immix Biopharma's stock symbol?

Immix Biopharma trades on the NASDAQ under the ticker symbol "IMMX."

Who are Immix Biopharma's major shareholders?

Immix Biopharma's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Bank of Montreal Can (0.11%). Insiders that own company stock include Ilya M Rachman and Sean Senn.
View institutional ownership trends.

How do I buy shares of Immix Biopharma?

Shares of IMMX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Immix Biopharma's stock price today?

One share of IMMX stock can currently be purchased for approximately $2.63.

How much money does Immix Biopharma make?

Immix Biopharma (NASDAQ:IMMX) has a market capitalization of $36.64 million.

How can I contact Immix Biopharma?

The official website for the company is www.immixbio.com. The company can be reached via phone at 310-651-8041.

This page (NASDAQ:IMMX) was last updated on 2/2/2023 by MarketBeat.com Staff